Supernus PharmaceuticalsUsage: TROKENDI XR® is indicated for initial monotherapy and adjunctive therapy in treating partial-onset and primary generalized tonic-clonic seizures, as well as seizures associated with Lennox-Gastaut syndrome in patients aged 6 and older. It is also indicated for preventive migraine treatment in patients aged 12 and older.